Across TCGA pan-cancer cohorts, TMEM119 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM119 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TMEM119 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM119 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and UCEC are the cancer types where TMEM119 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	1.000	0.541	.002	27	view →
LUAD	DFS	Tertile	All	0.795	0.502	.004	17	view →
UCEC	DFS	Median	All	0.852	0.960	.033	8	view →
PDAC	DFS	Median	III,IV	0.872	0.488	.016	8	view →
LSCC	OS	Quartile	III,IV	0.518	0.915	.038	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TMEM119 tumor-vs-normal RNA expression · all TMEM119 data types